Scolaris Content Display Scolaris Content Display

Comparison 1 Any methylxanthine vs control, Outcome 1 Failed apnoea reduction after 2 ‐ 7 days.
Figuras y tablas -
Analysis 1.1

Comparison 1 Any methylxanthine vs control, Outcome 1 Failed apnoea reduction after 2 ‐ 7 days.

Comparison 1 Any methylxanthine vs control, Outcome 2 Use of mechanical ventilation.
Figuras y tablas -
Analysis 1.2

Comparison 1 Any methylxanthine vs control, Outcome 2 Use of mechanical ventilation.

Comparison 1 Any methylxanthine vs control, Outcome 3 Tachycardia or feed intolerance.
Figuras y tablas -
Analysis 1.3

Comparison 1 Any methylxanthine vs control, Outcome 3 Tachycardia or feed intolerance.

Comparison 1 Any methylxanthine vs control, Outcome 4 PDA ligation.
Figuras y tablas -
Analysis 1.4

Comparison 1 Any methylxanthine vs control, Outcome 4 PDA ligation.

Comparison 1 Any methylxanthine vs control, Outcome 5 PMA at last oxygen therapy.
Figuras y tablas -
Analysis 1.5

Comparison 1 Any methylxanthine vs control, Outcome 5 PMA at last oxygen therapy.

Comparison 1 Any methylxanthine vs control, Outcome 6 PMA at last endo‐tracheal tube.
Figuras y tablas -
Analysis 1.6

Comparison 1 Any methylxanthine vs control, Outcome 6 PMA at last endo‐tracheal tube.

Comparison 1 Any methylxanthine vs control, Outcome 7 PMA at last positive pressure ventilation.
Figuras y tablas -
Analysis 1.7

Comparison 1 Any methylxanthine vs control, Outcome 7 PMA at last positive pressure ventilation.

Comparison 1 Any methylxanthine vs control, Outcome 8 Cognitive delay.
Figuras y tablas -
Analysis 1.8

Comparison 1 Any methylxanthine vs control, Outcome 8 Cognitive delay.

Comparison 1 Any methylxanthine vs control, Outcome 9 Chronic lung disease (BPD).
Figuras y tablas -
Analysis 1.9

Comparison 1 Any methylxanthine vs control, Outcome 9 Chronic lung disease (BPD).

Comparison 1 Any methylxanthine vs control, Outcome 10 Death before discharge.
Figuras y tablas -
Analysis 1.10

Comparison 1 Any methylxanthine vs control, Outcome 10 Death before discharge.

Comparison 1 Any methylxanthine vs control, Outcome 11 Cerebral palsy.
Figuras y tablas -
Analysis 1.11

Comparison 1 Any methylxanthine vs control, Outcome 11 Cerebral palsy.

Comparison 1 Any methylxanthine vs control, Outcome 12 Death or major disability by late infancy.
Figuras y tablas -
Analysis 1.12

Comparison 1 Any methylxanthine vs control, Outcome 12 Death or major disability by late infancy.

Comparison 1. Any methylxanthine vs control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Failed apnoea reduction after 2 ‐ 7 days Show forest plot

5

192

Risk Ratio (M‐H, Fixed, 95% CI)

0.44 [0.32, 0.60]

1.1 Theophylline vs. control

3

92

Risk Ratio (M‐H, Fixed, 95% CI)

0.42 [0.28, 0.63]

1.2 Caffeine vs. control

2

100

Risk Ratio (M‐H, Fixed, 95% CI)

0.46 [0.27, 0.78]

2 Use of mechanical ventilation Show forest plot

5

192

Risk Ratio (M‐H, Fixed, 95% CI)

0.34 [0.12, 0.97]

2.1 Theophylline vs. control

3

92

Risk Ratio (M‐H, Fixed, 95% CI)

0.38 [0.13, 1.16]

2.2 Caffeine vs. control

2

100

Risk Ratio (M‐H, Fixed, 95% CI)

0.2 [0.01, 3.66]

3 Tachycardia or feed intolerance Show forest plot

4

149

Risk Ratio (M‐H, Fixed, 95% CI)

4.69 [0.24, 89.88]

3.1 Theophylline vs. control

2

49

Risk Ratio (M‐H, Fixed, 95% CI)

4.69 [0.24, 89.88]

3.2 Caffeine vs. control

2

100

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 PDA ligation Show forest plot

1

827

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.21, 0.66]

4.1 Caffeine vs. control

1

827

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.21, 0.66]

5 PMA at last oxygen therapy Show forest plot

1

797

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐1.54, ‐0.26]

5.1 Caffeine vs. control

1

797

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐1.54, ‐0.26]

6 PMA at last endo‐tracheal tube Show forest plot

1

797

Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐1.03, ‐0.17]

6.1 Caffeine vs. control

1

797

Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐1.03, ‐0.17]

7 PMA at last positive pressure ventilation Show forest plot

1

797

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐1.32, ‐0.48]

7.1 Caffeine vs. control

1

797

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐1.32, ‐0.48]

8 Cognitive delay Show forest plot

1

715

Risk Ratio (M‐H, Fixed, 95% CI)

0.86 [0.69, 1.06]

8.1 Caffeine vs. control

1

715

Risk Ratio (M‐H, Fixed, 95% CI)

0.86 [0.69, 1.06]

9 Chronic lung disease (BPD) Show forest plot

1

805

Risk Ratio (M‐H, Fixed, 95% CI)

0.72 [0.58, 0.89]

9.1 Caffeine vs. control

1

805

Risk Ratio (M‐H, Fixed, 95% CI)

0.72 [0.58, 0.89]

10 Death before discharge Show forest plot

3

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.49 [0.14, 1.78]

10.1 Theophylline vs. control

2

72

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.05, 1.52]

10.2 Caffeine vs. control

1

82

Risk Ratio (M‐H, Fixed, 95% CI)

1.64 [0.16, 17.43]

11 Cerebral palsy Show forest plot

1

729

Risk Ratio (M‐H, Fixed, 95% CI)

0.60 [0.29, 1.25]

11.1 Caffeine vs. control

1

729

Risk Ratio (M‐H, Fixed, 95% CI)

0.60 [0.29, 1.25]

12 Death or major disability by late infancy Show forest plot

1

767

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.71, 1.01]

12.1 Caffeine vs. control

1

767

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.71, 1.01]

Figuras y tablas -
Comparison 1. Any methylxanthine vs control